Researchbreadcrumb separatorPresentationsbreadcrumb separator2024
Presentations 2024

 

HIV Drug Therapy Glasgow 2024, Glasgow, Great Britain, 10-13 November 2024

Poster presentation: 

  • Outcomes after the most common cancers in people with HIV  presented by Alisa Timiryasova on behalf of the RESPOND (International Cohort Consortium of Infectious Diseases) and D:A:D (The Data Collection on Adverse Events of Anti-HIV Drugs Study) study groups.
     
  • Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used Pre-exposure Prophylaxis in Europe; the PrEPaRe study  presented by Valentina Cambiano on behalf of the PrEPaRe study group.
     
  • Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia  presented by Erich Tusch on behalf of the RESPOND (International Cohort Consortium of Infectious Diseases) study group.
     
  • Changes in the ART coverage and viral suppression from 2020 to 2022 in Kyiv, Ukraine presented by Olga Fursa on behalf of the CARE study group.
     

 

Nordic HIV & Virology Conference 2024, Stockholm, Sweden, 25-27 September 2024

Poster presentation:

  • RESPONDing to Comtemporary Challenges for Pople Living with HIV: An Evolving Cohort Collaboration  presented by Bastian Neesgaard on behalf of RESPOND study group.POSTER 

      
     

 

ECCMID 2024, Barcelona, Spain, 27-30 April 2024

Poster presentations:

  • Trends in AIDS-defining illnesses among people living with HIV in Europe: results from the EuroSIDA study (2003-2022) presented by Wendy Bannister on behalf of the EuroSIDA Study Group. POSTER


     

 

Conference on Retrovirus and Opportunistic Infections (CROI 2024), Denver, Colorado, USA, 3-6 March 2024

Poster presentations:

  • Novel Biomarkers as Determinants of HBsAg Loss in Persons with HIV/HBV on Tenofovir  presented by Lorin Begré on behalf of the EuroSIDA Study Group. POSTER 
     
  • Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021  presented by Nadine Jaschinski on behalf of the RESPOND Study Group. POSTER  
     
  • Increased Cancer Risk With Low CD4 Counts Persists Despite Over 2 Years of Virological Suppression   presented by Jennifer Hoy on behalf of the RESPOND Study Group. POSTER

 


IWHOD 2024, Vilamoura, Portugal, 21-23 March 2024

Poster presentations:

  • Trends in AIDS-defining illnesses among people living with HIV in Europe: results from the EuroSIDA study (2003-2022) presented by Wendy Bannister on behalf of the EuroSIDA Study Group. POSTER

 

Login